Provided by Tiger Trade Technology Pte. Ltd.

Arq Inc.

2.21
-0.0900-3.91%
Post-market: 2.210.00000.00%19:30 EDT
Volume:159.60K
Turnover:352.51K
Market Cap:96.51M
PE:-1.77
High:2.39
Open:2.30
Low:2.17
Close:2.30
52wk High:7.82
52wk Low:1.54
Shares:43.67M
Float Shares:32.35M
Volume Ratio:0.79
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2467
EPS(LYR):-1.2700
ROE:-27.05%
ROA:-1.91%
PB:0.57
PE(LYR):-1.74

Loading ...

Arq Warns That Lack of Strategic Industry Partnerships Could Limit Corbin Facility Output and Weigh on Financial Performance

TIPRANKS
·
Mar 11

Arq price target lowered to $6.50 from $8 at Clear Street

TIPRANKS
·
Mar 11

Arq forecasts 2026 revenue of USD 120-125 million and adjusted EBITDA of USD 17-20 million

Reuters
·
Mar 10

Arq Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 10

Arq Shares Fall After Widening 4Q Loss, Restructuring

Dow Jones
·
Mar 10

Arq Q4 EPS $(1.20) Misses $(0.02) Estimate, Sales $29.431M Beat $28.606M Estimate

Benzinga Earnings
·
Mar 10

Arq CFO and Operating Chief to Depart

Dow Jones
·
Mar 10

Arq to pause GAC production

TIPRANKS
·
Mar 10

Arq reports Q4 EPS ($1.20) vs. (3c) last year

TIPRANKS
·
Mar 10

Arq Q4 net loss widens to USD 50 million as gross margin falls 23 percentage points to 13.6%

Reuters
·
Mar 10

Arq Inc Q4 Operating Income USD -51.226 Million VS. Ibes Estimate USD -694.2 Thousand

THOMSON REUTERS
·
Mar 10

Arq Inc Q4 Net Income USD -50.027 Million VS. Ibes Estimate USD -2.66 Million

THOMSON REUTERS
·
Mar 10

Press Release: Arq Reports Fourth Quarter and Full Year 2025 Results

Dow Jones
·
Mar 10

Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline

TIPRANKS
·
Mar 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 09

Arq Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
Mar 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05

Arq Inc. amends MidCap revolving credit agreement to extend reduced liquidity covenant

Reuters
·
Mar 04

Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131

TIPRANKS
·
Mar 03

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

GlobeNewswire
·
Mar 03